MacroGenics vs Nuvation Bio
MGNX and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGNX and NUVB compare
Nuvation Bio is the larger company, worth 9.8 times as much as MacroGenics ($1.3B against $138M).
Nuvation Bio grew revenue faster over the last twelve months (1084% versus 11.7% for MacroGenics).
MacroGenics keeps more of each dollar of sales as profit, with a net margin of −8.7% compared with −88.2% at Nuvation Bio.
MacroGenics scores higher on the StockData Score (5 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGNX | NUVB |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $1.3B |
| Share price | $2.17 | $3.84 |
| Change, 1 year | 35.6% | −18.1% |
| Change, 5 years | −88.4% | −53.0% |
| Beta (5Y) | 0.45 | 1.79 |
| Employees | 293 | 298 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× (better) | 7.9× |
| P/B | 3.2× (better) | 5.3× |
| FCF yield | −47.4% | – |
| Fair value | – | $1.94 |
| Margin of safety | – | −97.7% |
| Growth | ||
| Revenue growth (TTM) | 11.7% | 1084% (better) |
| Revenue growth, 5Y average | 7.3% | – |
| Profitability | ||
| Operating margin | −24.3% (better) | −81.0% |
| Net margin | −8.7% (better) | −88.2% |
| FCF margin | −39.1% | – |
| Return on equity | −32.6% (better) | −47.8% |
| Financial health | ||
| Debt / equity | – | 0.02 |
| Interest coverage | −2.4× (better) | −5.4× |
| Current ratio | 2.96 | 8.37 (better) |
| Altman Z-score | −4.00 | 0.09 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 76.4% | 66.5% |
| Held by insiders | 6.2% | 24.6% |
| Insider net buying, 12 months | −$129K (better) | −$4.5M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 8.3% | 23.4% |
Go deeper
- MGNX stock overview
- MGNX income statement
- MGNX valuation and score
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.